Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 5/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940739 | 1.00 | ALDH1A1 (0.64) | ALDH1A1GAATDP1POLBATM | |
| SCHEMBL21994252 | 0.84 | ALDH1A1 (0.69) | ALDH1A1GAATDP1POLBRAB9A | |
| SCHEMBL27596093 | 0.81 | ALDH1A1 (0.50) | ALDH1A1GAATDP1SMN1; SMN2CTSL | |
| SCHEMBL9656234 | 0.78 | POLB (0.69) | ALDH1A1GAATDP1POLBRAB9A | |
| SCHEMBL9656226 | 0.78 | POLB (0.69) | ALDH1A1GAATDP1POLBRAB9A | |
| SCHEMBL14938452 | 0.77 | POLB (0.68) | ALDH1A1GAAPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL11606677 | 0.75 | RAB9A (0.74) | ALDH1A1GAAPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL23794042 | 0.72 | METTL3 (0.82) | ATMMETTL3 | |
| SCHEMBL9653590 | 0.72 | — | — | |
| SCHEMBL14950347 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059160-A1 | Chemical Activators of Nicotinamide Mononucleotide adenylyltransferase 2 (NMNAT2) and Uses Thereof | TSINGHUA UNIVERSITY (CN) | 2025-02-20 | — | — | US | claimed |
| CN-115197126-A | Novel NMNAT enzyme agonist and preparation and application thereof | 清华大学 | 2022-10-18 | — | — | CN | claimed |
| WO-2020107221-A1 | CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF | TSINGHUA UNIVERSITY (CN) | 2020-06-04 | — | — | WO | claimed |
| US-20250059160-A1 | Chemical Activators of Nicotinamide Mononucleotide adenylyltransferase 2 (NMNAT2) and Uses Thereof | TSINGHUA UNIVERSITY (CN) | 2025-02-20 | — | — | US | disclosed |
| CN-115197126-A | Novel NMNAT enzyme agonist and preparation and application thereof | 清华大学 | 2022-10-18 | — | — | CN | disclosed |
| WO-2020107221-A1 | CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF | TSINGHUA UNIVERSITY (CN) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020107221-A1 | CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF | TSINGHUA UNIVERSITY (CN) | 2020-06-04 | — | — | WO | disclosed |
| US-8318782-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | FUJIFILM CORPORATION (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-1454903-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-2327702-A1 | Mitotic kinesin inhibitor | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-7759371-B2 | Thiadiazoline derivative | Kyowa Hakko Kinn Co., Ltd. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7425636-B2 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1847534-A2 | Thiadiazoline derivative | Kyowa Hakko Kogyo Co., Ltd (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213380-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN | 2007-07-05 | — | — | US | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1616866-A1 | M-STAGE KINESIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059160-A1 | Chemical Activators of Nicotinamide Mononucleotide adenylyltransferase 2 (NMNAT2) and Uses Thereof | NAMPT, NNMT, NAPRT | ALDH1A1 1017/4885GAA 448/4885TDP1 1003/4885 |
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | ALDH1A1 343/4885GAA 4130/4885TDP1 1546/4885 |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KIF15, KIF5A, KIF5B | ALDH1A1 2889/4885GAA 1882/4885TDP1 1281/4885 |
| US-20070213380-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | ALDH1A1 343/4885GAA 4130/4885TDP1 1546/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | ALDH1A1 343/4885GAA 4130/4885TDP1 1546/4885 |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | ALDH1A1 2889/4885GAA 1882/4885TDP1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.